{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:34Z","timestamp":1786982674022,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the 1\u00b73\u00b75 project for disciplines of excellence, West China Hospital, Sichuan University","award":["Grant. ZYJC21050"],"award-info":[{"award-number":["Grant. ZYJC21050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13555-023-00998-w","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:02:36Z","timestamp":1692849756000},"page":"2387-2401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab"],"prefix":"10.1007","volume":"13","author":[{"given":"Yue","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyao","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingke","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-2884","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"issue":"7","key":"998_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7326\/AITC201804030","volume":"168","author":"LM Psoriasis","year":"2018","unstructured":"Psoriasis LM. Psoriasis. Ann Intern Med. 2018;168(7):49\u201364.","journal-title":"Ann Intern Med"},{"issue":"1","key":"998_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther. 2021;11(1):235\u201352.","journal-title":"Dermatol Ther"},{"issue":"2","key":"998_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/biomedicines10020228","volume":"10","author":"A Motolese","year":"2022","unstructured":"Motolese A, Ceccarelli M, Macca L, et al. Novel therapeutic approaches to psoriasis and risk of infectious disease. Biomedicines. 2022;10(2):228.","journal-title":"Biomedicines"},{"issue":"2","key":"998_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","volume":"137","author":"P D\u00e1vila-Seijo","year":"2017","unstructured":"D\u00e1vila-Seijo P, Dauden E, Descalzo MA, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol. 2017;137(2):313\u201321.","journal-title":"J Invest Dermatol"},{"key":"998_CR5","unstructured":"WHO. Tuberculosis. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis. Accessed 30 May 2023"},{"issue":"4","key":"998_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"998_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1346-8138.15196","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201\u201322.","journal-title":"J Dermatol"},{"issue":"11","key":"998_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"998_CR9","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"WHO","year":"2018","unstructured":"WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018."},{"issue":"11","key":"998_CR10","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"K R\u00f8nholt","year":"2017","unstructured":"R\u00f8nholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"998_CR11","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/jdv.16254","volume":"34","author":"E Fowler","year":"2020","unstructured":"Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1449\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"998_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43\u201351.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"998_CR13","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"998_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017848","volume":"6","author":"R Loddenkemper","year":"2015","unstructured":"Loddenkemper R, Lipman M, Zumla A. Clinical aspects of adult tuberculosis. Cold Spring Harb Perspect Med. 2015;6(1): a017848.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"22","key":"998_CR15","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMra1405427","volume":"372","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127\u201335.","journal-title":"N Engl J Med"},{"key":"998_CR16","volume-title":"Global tuberculosis report 2022","author":"WHO","year":"2022","unstructured":"WHO. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. (Licence: CC BY-NC-SA 3.0 IGO)."},{"issue":"1","key":"998_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1183\/13993003.00235-2016","volume":"48","author":"L Gao","year":"2016","unstructured":"Gao L, Bai L, Liu J, et al. Annual risk of tuberculosis infection in rural China: a population-based prospective study. Eur Respir J. 2016;48(1):168\u201378.","journal-title":"Eur Respir J"},{"issue":"7","key":"998_CR18","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60(7):1884\u201394.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"998_CR19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s13555-022-00745-7","volume":"12","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Chen H, Zou Q, et al. The tuberculosis positive conversion rate among psoriasis patients treated with adalimumab and secukinumab: a single-center retrospective study in China. Dermatol Ther. 2022;12(6):1493\u2013500.","journal-title":"Dermatol Ther"},{"issue":"6","key":"998_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14512","volume":"33","author":"D Shu","year":"2020","unstructured":"Shu D, Zhang Z, Zhou EY, Ma X, Zhao Y. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study. Dermatol Ther. 2020;33(6):e14512.","journal-title":"Dermatol Ther"},{"issue":"5","key":"998_CR21","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1080\/09546634.2022.2062280","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Patruno C, Bongiorno MR, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. J Dermatolog Treat. 2022;33(5):2629\u201333.","journal-title":"J Dermatolog Treat"},{"key":"998_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijid.2019.11.023","volume":"91","author":"Q Yang","year":"2020","unstructured":"Yang Q, Ruan Q, Liu X, et al. Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: a clinical trial. Int J Infect Dis. 2020;91:182\u20137.","journal-title":"Int J Infect Dis"},{"key":"998_CR23","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3389\/fimmu.2020.02006","volume":"11","author":"C Carranza","year":"2020","unstructured":"Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, Torres M. Diagnosis for latent tuberculosis infection: new alternatives. Front Immunol. 2020;11:2006.","journal-title":"Front Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00998-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T11:07:18Z","timestamp":1695899238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00998-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00998-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}